Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Pulmonx CorporationNASDAQ: LUNG

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 17.4% from a year ago

Cash & equivalents stood at $61.57M at the end of Q1 FY2026, down 17.4% from a year earlier and down 12.1% from the prior quarter. Over 3 fiscal years it compounded at -11.7% a year.

Context

  • Cash & equivalents amounted to 51.3% of total assets at the end of Q1 FY2026, up 1.9 pp from a year earlier.
  • Cash & equivalents increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -17.4% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$61.57M-12.1% QoQ
Last fiscal yearDec 2025
$70.01M-1.3% YoY
Year agoMar 2025
$74.56M-17.4% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-17.4%——
1 year-1.3%——
3-year CAGR-11.7%——
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
70.01M USD
Year-over-year change
-1.3%
4-year CAGR
-17.1%

Cash & Equivalents vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's Mar 2026 cash & equivalents of $61.57M is the 3rd highest of the 10 companies compared; the peer median is $39.13M.
  • Its year-over-year change of -17.4% is the 9th highest of 10, against a peer median of -3.7%.
  • Cash & equivalents amounts to 51.3% of total assets for LUNG, versus a peer median of 40.5%.
LUNG Competitors Peer median
Cash & Equivalents for LUNG and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IMUXImmunic, Inc.Mar 2026$186.63M +1204.7%-47.5%98.4%
TCRXTScan Therapeutics, Inc.Mar 2026$128.06M -16.9%+8.3%63.4%
LUNGPulmonx CorporationMar 2026$61.57M -17.4%-11.7%51.3%
VXRTVaxart, Inc.Mar 2026$50.75M +76.8%+6.9%28.2%
HYPRHyperfine, Inc.Mar 2026$40.78M +23.2%-33.3%67.6%
PMVPPMV Pharmaceuticals, Inc.Mar 2026$39.13M -23.8%-29.5%40.5%
ACRVAcrivon Therapeutics, Inc. Common StockMar 2026$34.06M -13.0%+12.0%31.6%
ASRTAssertio Holdings, Inc.Mar 2026$33.71M -3.7%-46.0%16.0%
TELATELA Bio, Inc.Jun 2026$30.42M -13.0%+6.6%50.9%
RLMDRelmada Therapeutics, Inc.Mar 2026$9.78M +750.3%-13.5%4.2%
Peer median (excluding LUNG) $39.13M-3.7%-13.5%40.5%

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents148.48M101.74M83.55M70.91M70.01M
Short-term Investments31.56M39.4M33.56M30.58M0
Net Receivables6.92M9.28M13.02M13.79M12.07M
Inventory16.29M14.56M16.74M16.92M15.85M
Other Current Assets578K521K741K1.39M3.76M
Total Current Assets208M168.95M150.42M136.25M101.68M
Property, Plant & Equipment (Net)12.89M10.5M7.43M21.45M20.25M
Goodwill2.33M2.33M2.33M2.33M2.33M
Intangible Assets277K154K31K00
Long-term Investments10.94M5.92M14.39M00
Tax Assets00000
Other Non-current Assets731K5.81M3.17M2.82M5.03M
Total Non-current Assets27.17M24.72M27.36M26.6M27.61M
Total Assets235.17M193.68M177.78M162.85M129.29M
Account Payables1.58M1.76M1.5M3.83M3.91M
Short-term Debt91K90K2.16M3.18M1.32M
Tax Payables877K646K93K876K0
Deferred Revenue163K120K104K135K18K
Other Current Liabilities4.74M4.97M7.88M6.89M4.98M
Total Current Liabilities17.55M18.49M23.16M24.44M20.06M
Long-term Debt17.32M17.23M35.09M34M36.99M
Deferred Tax Liabilities37K94K114K87K69K
Deferred Revenue (Non-current)00000
Other Non-current Liabilities179K0000
Total Non-current Liabilities24.38M21.18M36.31M52.6M55.12M
Total Liabilities41.93M39.67M59.47M77.04M75.18M
Common Stock37K38K39K40K42K
Retained Earnings(291.4M)(350.32M)(411.16M)(467.56M)(521.56M)
Accumulated OCI1.71M1.58M2.64M2.11M2.36M
Other Stockholders Equity00000
Minority Interest00000
Total Equity193.24M154.01M118.32M85.81M54.12M
Total Debt26.46M24.4M41.42M56.47M56.36M
Net Debt(122.02M)(77.33M)(42.12M)(14.43M)(13.65M)

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.